recombinant human fgf4 rhfgf4 Search Results


recombinant human fgf4  (R&D Systems)
95
R&D Systems recombinant human fgf4
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Recombinant Human Fgf4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+fgf4+rhfgf4/Recombinant+Human+FGF-4+Protein/pm24067354-66-0-4
Average 95 stars, based on 1 article reviews
recombinant human fgf4 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
recombinant human fgf4 rhfgf4  (R&D Systems)
95
R&D Systems recombinant human fgf4 rhfgf4
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Recombinant Human Fgf4 Rhfgf4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+fgf4+rhfgf4/Recombinant+Human+FGF-4+Protein/pmc10280139-107-34-38
Average 95 stars, based on 1 article reviews
recombinant human fgf4 rhfgf4 - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
recombinant human fgf-4 protein, cf  (Bio-Techne corporation)
94
Bio-Techne corporation recombinant human fgf-4 protein, cf
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Recombinant Human Fgf 4 Protein, Cf, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+fgf4+rhfgf4/Recombinant+Human+FGF-4+Protein%2C+CF/bio-techne+corporation___235-f4-cf
Average 94 stars, based on 1 article reviews
recombinant human fgf-4 protein, cf - by Bioz Stars, 2026-10
94/100 stars
  Buy from Supplier
human gata-6 antibody  (Bio-Techne corporation)
96
Bio-Techne corporation human gata-6 antibody
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Human Gata 6 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+fgf4+rhfgf4/Human+GATA-6+Antibody/bio-techne+corporation___af1700
Average 96 stars, based on 1 article reviews
human gata-6 antibody - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
anti-nanog  (Cosmo Bio USA)
90
Cosmo Bio USA anti-nanog
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Anti Nanog, supplied by Cosmo Bio USA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+fgf4+rhfgf4/nanog+antibody/pmc06455974-281-82-88
Average 90 stars, based on 1 article reviews
anti-nanog - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
recombinant human fgf 4  (R&D Systems)
90
R&D Systems recombinant human fgf 4
Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or <t>Fgf4</t> treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.
Recombinant Human Fgf 4, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+human+fgf4+rhfgf4/Recombinant+Human+FGF-16+Protein/pm12475908-49-23-27
Average 90 stars, based on 1 article reviews
recombinant human fgf 4 - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

Image Search Results


Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or Fgf4 treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.

Journal: Development (Cambridge, England)

Article Title: Atypical protein kinase C couples cell sorting with primitive endoderm maturation in the mouse blastocyst.

doi: 10.1242/dev.093922

Figure Lengend Snippet: Fig. 2. aPKC enrichment and polarisation are downstream of FGF/ERK signalling. (A) Schematic of 2i or Fgf4 treatment. (B) Number of GATA4 cells in control and 2i conditions. (C) Number of polarised cells on the ICM surface per embryo. 20/20 control embryos had at least eight cells. 23/26 2i-treated embryos had 0-6 polarised cells. (D) Number of GATA4 cells in control and Fgf4-treated embryos. (E-H) Immunofluorescence for aPKC and GATA4 in the ICM. (E) Higher levels of aPKC in PrE cells of control embryos after 48 hours (arrows), but not in those treated with 2i (F). (G) Polarised apical aPKC in PrE cells in controls after 72 hours (arrowheads), but not in 2i- treated embryos (H). (I-M) Immunofluorescence as in E-H for Fgf4 treatment. Both control (I,K) and experimental (J,L,M) embryos have apical aPKC in cells on the ICM surface (arrowheads). All data are collected from three replicas of each experiment. **P<0.01, ***P<0.001, unpaired Student’s t-test. Bar charts display mean+s.e.m. n, number of embryos. Scale bars: 20 μm.

Article Snippet: Recombinant human FGF4 (rhFGF4, R&D Systems) was diluted at 500 ng/ml in KSOMAA in the presence of 1 μg/ml of heparin (Sigma) as described previously (Yamanaka et al., 2010).

Techniques: Control, Immunofluorescence

Fig. 7. Proposed model for PrE formation. ICM cells become primed towards a PrE or epiblast fate through the action of paracrine Fgf4. Sustained production of Fgf4 by epiblast precursors reinforces PrE fate, which is accompanied by aPKC enrichment in PrE precursors and upregulation of GATA4. aPKC would trigger survival signals in PrE cells that reach the ICM surface, which maintain their position. aPKC becomes polarised on the apical side of PrE cells at E4.5, when the PrE forms an epithelium.

Journal: Development (Cambridge, England)

Article Title: Atypical protein kinase C couples cell sorting with primitive endoderm maturation in the mouse blastocyst.

doi: 10.1242/dev.093922

Figure Lengend Snippet: Fig. 7. Proposed model for PrE formation. ICM cells become primed towards a PrE or epiblast fate through the action of paracrine Fgf4. Sustained production of Fgf4 by epiblast precursors reinforces PrE fate, which is accompanied by aPKC enrichment in PrE precursors and upregulation of GATA4. aPKC would trigger survival signals in PrE cells that reach the ICM surface, which maintain their position. aPKC becomes polarised on the apical side of PrE cells at E4.5, when the PrE forms an epithelium.

Article Snippet: Recombinant human FGF4 (rhFGF4, R&D Systems) was diluted at 500 ng/ml in KSOMAA in the presence of 1 μg/ml of heparin (Sigma) as described previously (Yamanaka et al., 2010).

Techniques: